A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

• Has histologically or cytologically confirmed diagnosis of non-small cell lungcancer (NSCLC)

• Has newly diagnosed Stage IIIB/IIIC NSCLC, not eligible for curative resection orcurative chemotherapy/radiation as determined by a multidisciplinary tumor boardand/or by radiation oncologist, surgeon, and medical oncologist or Stage IV (M1a,M1b, or M1c) by American Joint Committee on Cancer (AJCC) Staging Manual, Version 8

• Provides an archival tumor tissue sample (≤5 years) or newly obtained core,incisional, or excisional biopsy of a tumor lesion not previously irradiated toenable central laboratory testing of kirsten rat sarcoma (KRAS) G12C mutationstatus, PD-L1 status, and biomarker research

• If have had adverse events (AEs) due to previous anticancer therapies, must haverecovered to < Grade 1 or baseline

• If human immunodeficiency virus (HIV)-infected, must have well controlled HIV onantiretroviral therapy (ART)

• If Hepatitis B surface antigen (HBsAg) positive, have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load

• If a participant has a history of Hepatitis C virus (HCV) infection, HCV viral loadis undetectable

Exclusion Criteria:

• Has diagnosis of small cell lung cancer. For mixed tumors, if small cell elementsare present, the participant is ineligible

• Has active inflammatory bowel disease requiring immunosuppressive medication orprevious clear history of inflammatory bowel disease

• Has known history of, or active, neurologic paraneoplastic syndrome

• Has an active infection requiring systemic therapy, with exceptions

• Has uncontrolled, significant cardiovascular disease or cerebrovascular disease

• Has one or more of the following ophthalmological findings/conditions: intraocularpressure >21 mmHg and/or any diagnosis of glaucoma, diagnosis of central serousretinopathy, retinal vein occlusion, or retinal artery occlusion, diagnosis ofretinal degenerative disease

• Has received prior systemic anticancer therapy for their locally advanced ormetastatic NSCLC

• Has received radiation therapy to the lung that is >30 Gray within 6 months of startof study intervention

• Has received radiotherapy within 2 weeks of start of study intervention.Participants must have recovered from all radiation-related toxicities, not requiredcorticosteroids, and not have had radiation pneumonitis

• Has known active central nervous system metastases and/or carcinomatous meningitis

• Known additional malignancy that is progressing or has required active treatmentwithin the past 3 years

• Has active autoimmune disease that has required systemic treatment in the past 2years

• Has history of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids or has current pneumonitis/interstitial lung disease

• Is HIV-infected and has a history of Kaposi's sarcoma and/or MulticentricCastleman's Disease

• Has history of allogenic tissue/solid organ transplant

• Has not fully recovered from any effects of major surgical procedure